

Correction: Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity

Athanasios Papadas, Yun Huang, Alexander Cicala, Yaling Dou, Matteo Fields, Alicia Gibbons, Duncan Hong, Daniel J. Lagal, Victoria Quintana, Alejandro Rizo, Brolyn Zomalan and Fotis Asimakopoulos

Papadas, A., Huang, Y., Cicala, A., Dou, Y., Fields, M., Gibbons, A., Hong, D., Lagal, D.J., Quintana, V., Rizo, A., Zomalan, B. and Asimakopoulos, F. (2023) Emerging roles for tumor stroma in antigen presentation and anti-cancer immunity. *Biochem. Soc. Trans.* 51: 2017–2028. doi: <https://doi.org/10.1042/BST20221083>

The authors would like to correct a passage of text from the “Dual roles of a non-cellular stromal actor: the contrast between the immunoregulatory proteoglycan versican versus its immunostimulatory proteolytic fragment, versikine” section of their review.

The original text reads:

Mice with targeted disruption of the Glu441-Ala442 bond that generates versikine demonstrate developmental abnormalities (94, 99). In wound healing, disruption of the Glu441-Ala442 bond, thus generating versikine from VCAN-V1, attenuates inflammation and promotes healing (94).

This should instead read:

Mice with targeted disruption of the Glu441-Ala442 cleavage site that generates versikine demonstrate developmental abnormalities (94, 99). In wound healing, disruption of the Glu441-Ala442 cleavage site, thus abrogating versikine generation from VCAN-V1, attenuates inflammation and promotes healing (94).

The requested correction has been assessed and agreed by the Editorial Board.

Correction published:
10 January 2024